GLP-1 drugs increase risk of NAION vision loss
Combined clinical trial data show 6.4 cases of non-arteritic anterior ischemic optic neuropathy per 100,000 GLP-1 users each year, compared with 3.8 cases among those given a placebo or other comparison treatment, asahi.com reported.
The U.S. Food and Drug Administration issued a warning on Nov. 9 that diabetes and weight-loss medications like Mounjaro and Ozempic may increase the risk of this rare, sudden vision loss.
The condition, known as NAION, causes sudden, painless, and potentially permanent loss of vision. Following the data review, federal regulators asked pharmaceutical manufacturers to update prescription drug labels with explicit warnings regarding the ocular risk.
Off-Label Weight Loss Risks in Japan
Clinics in Japan have been prescribing GLP-1 drugs for weight loss outside their approved uses, asahi.com reported. The Japan Society for the Study of Obesity warned in October of reports of serious health problems associated with excessive weight loss from off-label use of such medications, including impaired consciousness.
What is NAION and which drugs carry FDA warnings?
What is NAION and how does it affect vision?
Non-arteritic anterior ischemic optic neuropathy occurs when blood flow to the optic nerve is temporarily or permanently blocked. This damage leads to sudden, painless, and frequently irreversible loss of sight in one or both eyes.
🚨BREAKING: FDA now requires a vision-loss warning on every GLP-1 label, from Ozempic and Wegovy to Mounjaro, Zepbound and Foundayo. The risk is NAION, a rare optic nerve event: 6.4 vs 3.8 cases per 100,000 patient-years across 126 trials.
Which specific medications are included in the FDA warning?
The regulatory warning covers approved GLP-1 drugs, specifically naming widely used treatments such as Mounjaro and Ozempic. Manufacturers of these drugs must update their prescribing information.
How common is this vision condition among patients taking GLP-1 drugs?
Clinical trial data reviewed by regulators revealed an incidence rate of 6.4 cases per 100,000 users annually. In comparison, individuals receiving placebos or alternative treatments experienced 3.8 cases per 100,000 each year.
Earlier coverage: FDA Mandates Vision Loss Warning for GLP-1 Drugs Including Ozempic and Zepbound
Worth a look